What Happened?
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations.
NeoGenomics announced revenue of $187.8 million, an increase of 11.9% compared to the same period in the previous year, surpassing forecasts of $183.8 million. The company also reported an adjusted earnings per share of $0.03, which was slightly better than the $0.02 analysts had anticipated. Despite reporting a negative operating margin, investors appeared to focus on the strong top-line performance, signaling confidence in the company's trajectory.
After the initial pop the shares cooled down to $10.16, up 0.1% from previous close.
Is now the time to buy NeoGenomics? Access our full analysis report here.
What Is The Market Telling Us
NeoGenomics’s shares are extremely volatile and have had 41 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 26 days ago when the stock gained 3.4% as news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations. The pharmaceutical and biotech sectors rallied for a second consecutive day following the announcement of a direct-to-consumer prescription drug selling website. A key driver for the optimism is a deal between Pfizer and the administration, allowing the company to avoid potential tariffs by reducing drug prices. This outcome is seen as a relief for the industry, which had braced for more severe measures. The move has reduced uncertainty in the sector, with other major players like Eli Lilly reportedly in negotiations for a similar agreement, signaling a potentially favorable new landscape for drugmakers.
NeoGenomics is down 38.4% since the beginning of the year, and at $10.16 per share, it is trading 45.4% below its 52-week high of $18.61 from January 2025. Investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at an investment worth $254.96.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.
